Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Varenicline-Methamphetamine Interaction Study (2008)

25 juillet 2012 mis à jour par: Richard De La Garza, Baylor College of Medicine

A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline In Methamphetamine-Dependent Volunteers Receiving Methamphetamine

The primary aim of the study is to determine the safety and tolerability of treatment with Varenicline in methamphetamine-dependent volunteers. The investigators also seek to determine the effects of treatment with Varenicline, as compared to placebo, on craving for methamphetamine or cigarettes following exposure to methamphetamine and smoking cues, respectively. The effects of treatment with Varenicline, as compared to placebo, on subjective effects produced by administration of methamphetamine or placebo will be attempted to be determined. Lastly, the investigators hope to determine the effects of treatment with Varenicline, as compared to placebo, on reinforcing effects produced by administration of methamphetamine or placebo.

Aperçu de l'étude

Description détaillée

See Brief Summary

Type d'étude

Interventionnel

Phase

  • La phase 1

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 55 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • English speaking volunteers who are not seeking treatment at the time of the study
  • Be between 18-55 years of age
  • Meet DSM-IV criteria for MA dependence
  • Must be cigarette smokers, defined as smoking 10 or more cigarettes per day by self-report
  • Have a self-reported history of using MA by the smoked or IV route and provide at least one MA-positive urine prior to admission
  • Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 105-150 mm Hg systolic and 45-90 mm HG diastolic; this criterion must be met within 2 days of admission
  • Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total Bilirubin, ALT, AST, and alkaline phosphatase) < 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 x the upper limit of normal
  • Have a baseline EKG that demonstrates normal sinus rhythm, normal conduction (including QTc), and no clinically significant arrhythmias
  • Have a medical history and brief physical examination demonstrating no clinically significant contradictions for study participation, in the judgment of the admitting physician or nurse practitioner and the principal investigator

Exclusion Criteria:

  • Have any history or evidence suggestive of seizure disorder or brain injury
  • Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure
  • Have neurological or psychiatric disorders, such as: psychosis, bipolar illness or major depression as assessed by MINI; organic brain disease or dementia assessed by clinical interview; history of any psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months assessed by MINI and/or current suicidal ideation/plan as assessed by MINI
  • Have evidence of clinically significant heart disease or hypertension, as determined by the PI
  • Have a family history in first-degree relatives of early cardiovascular morbidity or mortality, as determined by the PI
  • Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease
  • Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication
  • Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, upon hospital admission, and at the end of study participation
  • Have asthma or currently use alpha or beta agonists, theophylline, or other sympathomimetics
  • Have any other illness, condition, or use of psychotropic medications, which in the opinion of the PI and/or the admitting physician or nurse practitioner would preclude safe and/or successful completion of the study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Répartition: Randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo
Matching oral placebo capsules as control.
Matching oral placebo capsules as control.
Autres noms:
  • Pilule de sucre
Comparateur actif: Varenicline
See assigned interventions.
Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
Autres noms:
  • Chantix

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Effects of varenicline and methamphetamine on cardiovascular measures.
The safety of MA administration during treatment will be assessed by reporting of adverse events (AEs), and using ECG recording, and heart rate and blood pressure measurements. Digital 12-lead EKG will also be recorded prior to randomization. Blood pressure and heart rate will be measured from 15 min prior to MA or placebo dosing until 2 h after dosing. In addition, heart rate and blood pressure will be assessed throughout the inpatient portion of the protocol.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Effects of varenicline and methamphetamine on subjective measures
Efficacy will be assessed by measuring effects of treatment on subjective and reinforcing effects produced by administration of MA and craving produced by exposure to drug cues. Other diagnostic measures and assessment instruments will be used to further characterize the study population.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Richard De La Garza, II, PhD, Baylor College of Medicine

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 janvier 2008

Achèvement primaire (Réel)

1 août 2008

Achèvement de l'étude (Réel)

1 août 2008

Dates d'inscription aux études

Première soumission

11 août 2008

Première soumission répondant aux critères de contrôle qualité

11 août 2008

Première publication (Estimation)

13 août 2008

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

27 juillet 2012

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 juillet 2012

Dernière vérification

1 juillet 2012

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • H-22707
  • DPMC (Autre identifiant: NIDA)
  • P50DA018185 (Subvention/contrat des NIH des États-Unis)
  • 2P50DA018197-06 (Subvention/contrat des NIH des États-Unis)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Abus de substance

Essais cliniques sur Placebo

3
S'abonner